Thyroid hormone receptor beta in Metabolic dysfunction-associated steatohepatitis

MightyRayn panel synthesis

OmniRayn’s reading of this landscape — our interpretation, not a registry fact

This is the target that broke the drought — the first approved therapeutic in a disease that had none — and the useful reading is what the approval did NOT settle. The pivotal 52-week trial reported disease resolution in roughly 26 to 30 percent of treated patients against 9.7 percent on placebo, and fibrosis improvement in about 24 to 26 percent against 14.2 percent. Both are real and both are significant. They also mean that around seven in ten treated patients did not achieve resolution, and that the fibrosis margin over placebo is roughly ten percentage points. The liver-related OUTCOMES trial that would turn a biopsy endpoint into a clinical one is still running. The competitive structure is unusual. One sponsor holds the approval and is now spending on adjacent populations — cirrhosis, post-liver-transplant recurrence, post-approval use outside the registrational geography — while three separate challengers pursue the same receptor, and the newest of them enters with a COMBINATION hypothesis rather than monotherapy. That is what a field looks like when the first drug is believed to be necessary but not sufficient. One caution the trial records will not give you: the review literature names the scale of PLACEBO RESPONSES as an open problem in this disease, and the placebo arms across the trials on this page and our FGF21 landscape range from about 10 to 20 percent on comparable endpoints. When the placebo response moves that much between studies, cross-trial comparison of the active arms is unsafe — which is precisely the trap in the indirect ranking discussed on the FGF21 page.

Programs and primary evidence

Method and limits

• Programs are enumerated from primary registries (ClinicalTrials.gov, PubMed). A program appears here only if a primary record links this target to this indication as a therapeutic hypothesis — associations and risk markers are excluded by design.
• Every claim above carries the identifier it rests on. We report what the record states; we do not assert efficacy, and computational findings are pending wet-lab confirmation.
• Absence is not evidence of absence: unregistered, non-US and stealth-stage programs are not visible to these sources.
• This page refreshes monthly (no net-new primary entity in 211 days). Mechanism classifications are our reading of the public record and may be revised.